Want to see JP:2929 full AI Analyst Report?
2929 Stock Chart & Stats
¥679.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥679.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥513.00 - ¥1,064.00
Previous CloseN/A
Volume159.60K
Average Volume (3M)110.46K
Market Cap
¥17.24B
Enterprise Value¥23.93B
Total Cash (Recent Filing)¥8.77B
Total Debt (Recent Filing)¥17.21B
Price to Earnings (P/E)40.4
Beta0.81
Next Earnings
Sep 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.65%
Share Statistics
EPS (TTM)14.72
Shares Outstanding29,079,000
10 Day Avg. Volume122,950
30 Day Avg. Volume110,460
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)2.21
Price to Sales (P/S)0.39
P/FCF Ratio-12.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)51.6
Revenue Forecast (FY)¥67.00B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA consistent revenue increase provides durable evidence of sustained consumer demand for the company's nutraceutical products. Over 2–6 months this supports predictable top-line cash inflows, preserves scale benefits in production/marketing, and underpins longer-term product development investment.
High Gross MarginsVery high gross margins create a structural buffer to absorb higher SG&A or input-cost shocks while still enabling profitable SKUs. This margin profile supports reinvestment in R&D and marketing and gives flexibility to defend pricing and margin sustainability over multiple quarters.
Improved LeverageMaterial deleveraging reduces interest burden and improves financial resilience. A lower debt-to-equity ratio increases capacity to fund product development, marketing, or working capital without urgent refinancing, strengthening the balance sheet for medium-term strategic initiatives.
Bears Say
Weak Cash GenerationNegative operating and free cash flows are a structural concern: they constrain the company's ability to self-fund growth, pay dividends, or absorb shocks. Persisting cash deficits require external financing, which can dilute returns or limit strategic options over the medium term.
Sharp Profitability DeclineA collapse in net margin undermines return generation and erodes retained earnings available for reinvestment. Lower profitability reduces ROE and limits capacity to compete on marketing or innovation, posing a lasting headwind to restoring healthy earnings without structural cost or pricing fixes.
Falling Operational MarginsDeclining EBIT/EBITDA margins point to rising operating costs or weaker pricing power. This trend pressures cash flow conversion and reduces room for sustained investment in R&D and brand building, creating a multi-quarter risk to competitiveness if margins do not recover.
Pharma Foods International Co., Ltd. News
2929 FAQ
What was Pharma Foods International Co., Ltd.’s price range in the past 12 months?
Pharma Foods International Co., Ltd. lowest stock price was ¥513.00 and its highest was ¥1064.00 in the past 12 months.
What is Pharma Foods International Co., Ltd.’s market cap?
Pharma Foods International Co., Ltd.’s market cap is ¥17.24B.
When is Pharma Foods International Co., Ltd.’s upcoming earnings report date?
Pharma Foods International Co., Ltd.’s upcoming earnings report date is Sep 14, 2026 which is in 59 days.
How were Pharma Foods International Co., Ltd.’s earnings last quarter?
Pharma Foods International Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥26.42 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pharma Foods International Co., Ltd. overvalued?
According to Wall Street analysts Pharma Foods International Co., Ltd.’s price is currently Overvalued.
Does Pharma Foods International Co., Ltd. pay dividends?
Pharma Foods International Co., Ltd. pays a Semiannually dividend of ¥12.5 which represents an annual dividend yield of 3.65%. See more information on Pharma Foods International Co., Ltd. dividends here
What is Pharma Foods International Co., Ltd.’s EPS estimate?
Pharma Foods International Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharma Foods International Co., Ltd. have?
Pharma Foods International Co., Ltd. has 29,079,000 shares outstanding.
What happened to Pharma Foods International Co., Ltd.’s price movement after its last earnings report?
Pharma Foods International Co., Ltd. reported an EPS of ¥26.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.376%.
Which hedge fund is a major shareholder of Pharma Foods International Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharma Foods International Co., Ltd.
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a specific egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg. Additionally, the company offers iHA, a compound recognized for stimulating the body's hyaluronic acid production. Furthermore, Pharma Foods International Co., Ltd. has entered into a licensing arrangement with Mitsubishi Tanabe Pharma Corporation for a novel therapeutic antibody designed to combat autoimmune conditions. The firm was founded in 1997 and maintains its corporate headquarters in Kyoto, Japan.
Technical Analysis
―
Tsumura & Co
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―